Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention.

ABSTRACT: This article seeks to analyze the clinical trials concerning the newly approved eptinezumab to assess its efficacy, safety, and application to current clinical practice. The Institute of Health US National Library of Medicine Clinical Trials, PubMed, and Cochrane Library databases were searched for relevant abstracts, journal articles, and other published sources. Search terms included eptinezumab, Vyepti^®, and ALD403. Relevant English-language articles were evaluated and included in the narrative. Two randomized controlled trials compared quarterly infusions of eptinezumab 100 mg, eptinezumab 300 mg, and placebo in chronic and episodic migraine sufferers. In episodic migraine, eptinezumab resulted in a reduction of approximately 4 monthly migraine days, which was significant co

SUBMITTER: Morgan KW 

PROVIDER: S-EPMC8511911 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature